Neximmune Inc (NEXI)
$3.35
+0.09
(+2.76%)▲
Live
Insights on Neximmune Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 116.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 340.0%
Performance
- $3.26$3.39$3.35
2.7%
Downside
Day's Volatility :3.85%
Upside
1.18%
- $1.25$28.69$3.35
62.69%
Downside
52 Weeks Volatility :95.64%
Upside
88.32%
Returns
| Period | Neximmune Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -36.58% | 1.7% | 0.0% |
6 Months | -23.83% | 11.3% | 0.0% |
1 Year | -67.07% | 5.4% | 1.3% |
3 Years | -99.32% | 13.9% | -22.1% |
Highlights
Market Capitalization | 4.7M |
Book Value | $3.29 |
Earnings Per Share (EPS) | -30.82 |
Wall Street Target Price | 2.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -70.62% |
Return On Equity TTM | -180.64% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -28.2M |
Diluted Eps TTM | -30.82 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 40.3%
Technicals Summary
Sell
Neutral
Buy
Neximmune Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Neximmune Inc | -43.3% | -23.83% | -67.07% | -99.32% | -99.49% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Neximmune Inc | 0.01 | NA | NA | 0.0 | -1.81 | -0.71 | NA | 3.29 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Neximmune Inc | Buy | $4.7M | -99.49% | 0.01 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Slate Path Capital LP
2.84%Adage Capital Partners Gp LLC
2.46%EPIQ Capital Group, LLC
1.20%PNC Financial Services Group Inc
0.97%Comerica Bank
0.25%Tower Research Capital LLC
0.14%
Company Information
neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Organization | Neximmune Inc |
Employees | 6 |
CEO | Ms. Kristi Jones R.Ph. |
Industry | Healthcare |
